Critical Survey: OnKure Therapeutics (OKUR) & Its Rivals

OnKure Therapeutics (NASDAQ:OKUR) is one of 1,044 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare OnKure Therapeutics to related companies based on the strength of its profitability, dividends, risk, valuation, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OnKure Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0	0	2	1	3.33
OnKure Therapeutics Competitors	7558	20801	48343	1185	2.55

OnKure Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 125.90%. As a group, “Pharmaceutical preparations” companies have a potential upside of 74.58%. Given OnKure Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than its rivals.

Volatility & Risk

OnKure Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, OnKure Therapeutics’ rivals have a beta of 1.00, meaning that their average share price is 0% more volatile than the S&P 500.

Valuation & Earnings

This table compares OnKure Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OnKure Therapeutics	N/A	-$77.39 million	-1.36
OnKure Therapeutics Competitors	$1.71 billion	$155.47 million	-5.04

OnKure Therapeutics’ rivals have higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares OnKure Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
OnKure Therapeutics Competitors	-3,610.82%	-270.26%	-33.18%

Summary

OnKure Therapeutics beats its rivals on 9 of the 13 factors compared.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.